Press releases
- Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
- Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
- Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
- Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
- Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
More ▼
Key statistics
On Tuesday, Mirum Pharmaceuticals Inc (08D:MUN) closed at 23.00, 3.60% above its 52-week low of 22.20, set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.00 |
---|---|
High | 23.00 |
Low | 23.00 |
Bid | -- |
Offer | -- |
Previous close | 23.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 47.13m |
Free float | 45.96m |
P/E (TTM) | -- |
Market cap | 1.13bn USD |
EPS (TTM) | -3.82 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 07:07 BST.
More ▼